News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 — Eli Lilly is making tirzepatide, branded as Zepbound for weight loss, available in vials for patients who pay out-of-pocket.
News Release - Eli Lilly and Company
Nov 8, 2023 — Lilly is putting a commercial savings card program in place that will help people who may benefit from Zepbound better access it. People who are commercially insured with coverage for Zepbound may be eligible to pay as low as $25 for a 1-month or 3-month prescription.
Eli Lilly releases new form of weight loss drug Zepbound for half …
Aug 27, 2024 — Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the...
What to know about Zepbound, Eli Lilly’s new weight loss drug - NBC News
Nov. 9, 2023, 2:00 AM PST. By Berkeley Lovelace Jr. A new weight loss drug has been approved that promises to be the most effective medication yet. How is Zepbound, the weekly injectable drug...
Zepbound price cut: Eli Lilly lowers cost of weight loss drug - NBC News
Aug 27, 2024 — Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and ease supply ...
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to ...
Nov 8, 2023 — The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during clinical trials.
Zepbound: FDA approves Eli Lilly’s diabetes drug Mounjaro for …
Nov 8, 2023 — The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes ...
Weight loss drug Zepbound is now available, Eli Lilly says
Dec 6, 2023 — Drug manufacturer Eli Lilly announced Tuesday that its flagship weight loss medication, Zepbound, is now available for patient use. Tirzepatide, its active ingredient, had been approved by...
News Release - Eli Lilly and Company
Dec 11, 2023 — Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks